Joint position paper on considerations for switching between biologics and biosimilar medicinal products
Three international industry associations release a joint position paper on considerations for switching between biologics and biosimilar medicinal products.
On 9 March 2017, the industry associations European Biopharmaceutical Enterprises ("EBE"), European Federation of Pharmaceutical Industries and Associations ("EFPIA"), and International Federation of Pharmaceutical Manufacturers and Associations ("IFPMA") released a position paper on "Considerations for physicians on switching decisions regarding biosimilars".
In the position paper, they state that:
- "…any decision to switch should be made on a case-by-case basis and must be patient, disease and product specific. A "one size fits all" approach is not appropriate."
- "Switching between biosimilars represents an unknown, and one that harbours considerable uncertainty."
- "…the physician should retain decision-making autonomy and have unrestricted choice of products to prescribe."
Read the position paper here